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Abstract objective Recording and reporting systems borrowed from the DOTS framework for tuberculosis
control can be used to record, monitor and report on chronic disease. In a primary healthcare clinic run
by UNRWA in Amman, Jordan, serving Palestine refugees with hypertension, we set out to illustrate the
method of cohort reporting for persons with hypertension by presenting on quarterly and cumulative
case ﬁnding, cumulative and 12-month analysis of cohort outcomes and to assess how these data may
inform and improve the quality of hypertension care services.
method This was a descriptive study using routine programme data collected through E-Health.
results There were 97 newly registered patients with hypertension in quarter 1, 2012, and a total of
4130 patients with hypertension ever registered since E-Health started in October 2009. By 31 March
2012, 3119 (76%) of 4130 patients were retained in care, 878 (21%) had failed to present to a
healthcare worker in the last 3 months and the remainder had died, transferred out or were lost to
follow-up. Cumulative and 12-month cohort outcome analysis indicated deﬁciencies in several com-
ponents of clinical performance related to blood pressure measurements and fasting blood glucose tests
to screen simultaneously for diabetes. Between 8% and 15% of patients with HT had serious compli-
cations such as cardiovascular disease and stroke.
conclusion Cohort analysis is a valuable tool for the monitoring and management of non-
communicable chronic diseases such as HT.
keywords hypertension, diabetes mellitus, Palestine refugees, Jordan, cohort reports
Introduction
The diagnosis and treatment of hypertension (HT) has been
one of medicine’s great successes over these past 50 years,
but despite this achievement the global burden of HT is
immense and increasing. In 2000, the estimated number of
adults with HT globally was 972 million, with the numbers
expected to rise to 1.56 billion by 2025 (Editorial 2007).
Lifestyle factors such as lack of physical exercise, excess
salt, alcohol and tobacco are inexorably linked to this
disease burden. The Global Burden of Disease study
estimated that for the year 2001, about 7.6 million
(13.5%) of all deaths and 92 million (6%) of all DALYs
(disability-adjusted life years) were caused by hypertension,
with high blood pressure causing 54% of strokes and 25%
of cardiovascular disease worldwide, much of this in young
age groups (Lawes et al. 2008).
In many parts of the world, a major obstacle to the
control of blood pressure–related diseases is the absence of
appropriate primary healthcare services (MacMahon et al.
2008). Most such services provide only episodic, unstruc-
tured and unmonitored care with little or no record about
previous visits and no information about HT incidence and
prevalence, treatment outcomes, associated morbidity or
mortality. These services need to change and adapt to
provide continuing chronic care. We have suggested
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systems borrowed from the ‘DOTS’ (directly observed
therapy, short course) framework for tuberculosis control
can be used to record, monitor and report on chronic
disease (Harries et al. 2008), and indeed, this has been
performed in Malawi for the management of HIV⁄AIDS
(Harries et al. 2009a) and diabetes mellitus (Allain et al.
2011).
The United Nations Relief and Works Agency for
Palestine Refugees in the Near East (UNRWA) has been
working in the region for 62 years and provides education,
health and social services for about ﬁve million Palestine
refugees in Jordan, Lebanon, Syria, the West Bank and
Gaza Strip (UNRWA 2011). UNRWA currently provides
services from 138 primary healthcare (PHC) centres and
one hospital in the West Bank, with an important
component being the diagnosis and care of non-commu-
nicable diseases, particularly DM and HT (United Nations
Relief and Works Agency for Palestine Refugees in the
Near East (UNRWA) 2011). Prevalence of DM and HT
among UNRWA served populations aged 40 years and
older is 11.4% and 17.5%, respectively, and in 2011,
almost 211 000 people with DM and⁄or HT were being
cared for at UNRWA clinics in the region (United Nations
Relief and Works Agency for Palestine Refugees in the
Near East (UNRWA) 2011).
In 2009, UNRWA started an electronic health record
system (E-Health), which currently operates in six PHC
clinics in Jordan. In Nuzha PHC clinic, Amman, where the
E-Health system has been operational for about
30 months, we developed a cohort reporting system for
Palestine refugees with HT. The aim of this study is to
illustrate the methodology by reporting on quarterly and
cumulative case ﬁnding, cumulative and 12-month cohort
outcome analysis and assess how these data may usefully
inform and improve the quality of HT management
services.
Methods
This is a retrospective descriptive study of the use of the E-
Health and cohort reporting framework to monitor
persons with HT at Nuzha PHC Clinic.
The Arab-Israeli war of 1948 created the largest refugee
population in the world, with 2.8 million people residing
outside the occupied Palestinian territory in Syria, Lebanon
and Jordan (Sabatinelli et al. 2009). Health care for these
people is provided mainly by UNRWA. Two million
refugees reside in Jordan where they are entitled to full
citizenship except for those who arrived from the Gaza
strip. These refugees are generally a young population.
Over the last 60 years, the incidence of communicable
disease has gradually fallen, and as the lifestyle has
changed and life expectancy has risen, non-communicable
diseases, especially DM and HT, have emerged as major
health problems. Rates of DM and HT reported by
UNRWA are in fact similar to those reported for
Palestine refugees living within the occupied Palestinian
territory of the West Bank and Gaza (Giacaman et al.
2009; Husseini et al. 2009), with similar risk factors of
obesity, lack of physical activity and increasingly unhealthy
diets.
The study was conducted in Nuzha PHC Clinic in
Amman, Jordan’s capital city. Jordan is a country of six
million people, including two million registered Palestine
refugees, of whom 17% live inside 10 camps. There are 24
PHC clinics that are run by UNRWA staff, accessed by
more than 50% of registered Palestine refugees in Jordan.
Nuzha PHC clinic is located outside of the camps and
serves a catchment population of 55 000 refugees. The
clinic is staffed by four doctors and a variable number of
nurses and support staff. All screening, diagnosis and
treatment services at the clinic are provided free of charge.
All Palestine refugees who attend the clinic are screened
for HT if they are 40 years or older, if they are judged to be
at risk of non-communicable diseases and if they are pre-
conception or pregnant women. HT screening is performed
by the trained nurse and the diagnosis is conﬁrmed by a
medical ofﬁcer if the blood pressure is ‡140⁄90 mmHg on
several separate occasions. Those who do not have HT are
followed up and screened every 6 months (UNRWA 2009).
Persons diagnosed with HT are clinically assessed for
complications and comorbidities such as diabetes mellitus
(deﬁned as two fasting blood glucose measurements, both
of which must be ‡126 mg⁄dl (UNRWA Health Depart-
ment 2009; WHO 2006), and these data along with
demographic and clinical information are recorded in E-
Health system. Patients are classiﬁed as having new or
previously diagnosed hypertension, the diagnosis made
either within or outside of the UNRWA system, and a
record is also made about whether the patient has been
transferred in from another UNRWA clinic.
Patients are managed according to a standard algorithm
with diet and lifestyle advice and different classes of
antihypertensive drugs that include beta-blockers, diuret-
ics, calcium channel blockers, angiotensin-converting
enzyme (ACE) inhibitors and methyldopa (Box 1).
Methyldopa is mainly used for pregnancy-induced hyper-
tension, and there are plans to replace it with labetolol.
Patients with uncontrolled HT are seen weekly or monthly
until their blood pressure is <140⁄90 mmHg, and they are
then followed every 3 months. During the quarterly visit,
the patients are supposed to be assessed as follows: body
mass index, blood pressure measurement and the
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blindness, end-stage renal failure, myocardial infarction,
congestive cardiac failure, stroke and above ankle
amputation). Urine is assessed for glucose and protein
every 6 months. Once in every 12 months, all patients with
HT are expected to have fasting blood tests for total
cholesterol and serum creatinine and those without DM
are also expected to be screened for the disease with fasting
blood glucose.
The electronic health system (E-Health) was set up in
2009 for non-communicable diseases, maternal health,
child health and general outpatients and is currently
operational in six UNRWA clinics in Jordan, including
Nuzha PHC clinic. All clinical information, including
prescriptions and laboratory requests, are managed
electronically, with patient baseline and follow-up data
stored in E-Health. There are electronic keyboard
operated work stations in every clinic room, including the
pharmacy and laboratory, and these are connected to a
central server that stores the data. Clinicians and nurses use
the computers (password protected) at the point-of-care
to enter patient information during clinical encounters.
New patients are registered by a clerk and thereafter
clinicians and nurses can access that patient’s electronic
data ﬁle using the patient health card and identiﬁcation
number. In addition to being an electronic tool to facilitate
good clinical care, E-Health also allows cohort data to be
collected.
All patients who were registered and entered into the
E-Health system with HT from 1 October 2009 to 31
March 2012 in Nuzha PHC Clinic were included in the
analysis. Patient data were obtained from the Clinic
E-Health system. Data variables for the cohorts included:
age, sex, diagnosis of HT, associated DM, new or previous
diagnosis of HT, diagnosis made inside or outside
UNRWA health centres, whether the patient has been
transferred in from another UNRWA clinic, current
treatment outcome status as of 31 March 2012, current
management, quarterly blood pressure measurements,
whether quarterly or annual screening tests (and results)
had been conducted and the presence or absence of late
complications. Deﬁnitions of variables for the management
of patients and for the cohort reports are shown in Table 1.
For this study, data were collected and aggregated into
four cohort reports: (i) Quarterly Registration (patients
with HT newly registered in quarter 1, 2012 – from 1
January to 31 March 2012; (ii) Cumulative Registration
(total number of patients with HT ever registered up to 31
Box 1 Guidance for the management of hypertension in Nuzha
Primary Health Clinic, Jordan
Step 0 Lifestyle modiﬁcation
If BP still uncontrolled, then low dose of diuretic
such as hydrochlorothiazide or beta-blocker
Step 1 >55 years – calcium channel blocker or diuretic
£55 years – ACE inhibitor or beta-blocker
Step 2 ACE inhibitor or beta-blocker PLUS calcium
channel blockers or diuretics
Step 3 ACE inhibitor or beta-blocker PLUS calcium
channel blockers and diuretics
Step 4 Refer to hospital for investigation and new/
management plan
BP, blood pressure; ACE inhibitor, angiotensin-converting
enzyme inhibitor.
Table 1 Deﬁnitions for the management
and recording of patients with hypertension
(HT) for the cohort reports
Quarterly and Cumulative Registrations
New diagnosis Date of registration occurs within four weeks
of date of diagnosis
Previous diagnosis Date of registration occurs four weeks or later
from date of diagnosis
Transferred in Previously registered in another UNRWA clinic
and now transferred to the current clinic
Diabetes mellitus Two fasting blood glucose measurements, both of
which must be ‡126 mg⁄dl
Cumulative treatment outcomes and 12-month survival analysis
Remaining in care Alive and in care and seen by a doctor or nurse
during quarter 1, 2012
Dead Died at any time from any cause
Transferred out Permanently transferred out from the clinic
to another clinic
No quarterly attendance Not seen in the clinic in quarter 1, 2012, by a
doctor or a nurse
Lost to follow-up No quarterly attendances on four consecutive
occasions at the clinic
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(iii) Cumulative Outcomes (outcomes of all patients with
HT ever registered up to 31 March 2012, with the
outcomes censored on 31 March); and (iv) 12-month
Cohort Outcome Analysis (the outcomes of patients with
HT who were newly registered in quarter 1, 2011 – from 1
January to 31 March 2011 – with data censored on 31
March 2012). The data for these four types of cohort
reports are presented and analysed in terms of assessment
and impact on programme performance.
The data for the study included retrospectively collected
routine patient information on HT. Data were aggregated
for the cohort reporting and no individual patient
identiﬁers were used. Approval for the study was obtained
from UNRWA Headquarters and it was decided that no
local ethical approval was required. Ethical approval for
reporting on the study was obtained from the Union Ethics
Advisory Group.
Results
The four cohort analyses and the results from Nuzha PHC
Clinic are shown in Tables 2–5. The number of new
quarterly HT registrations at the clinic and their demo-
graphic and clinical characteristics for quarter 1, 2012 are
shown in Table 2. The main points of interest are that 86%
of new registrations were 40 years and older, 54% were
new diagnoses and just over half the patients had associ-
ated DM at the time of registration. There were 4130
patients with HT cumulatively ever registered at Nuzha
PHC since E-Health was set up, including those patients
newly registered between January and March 2012. Their
characteristics are shown in Table 3. The cumulative
cohort was fairly similar to the new quarter registrations
except there were more women, more patients with a
previous diagnosis of HT and more patients with a
diagnosis made from within UNRWA sites.
The outcomes of the whole cumulative cohort with data
censored on 31 March 2012 are shown in Table 4. For all
4130 patients with HT, the primary outcome data shown
were as follows: those remaining in care by 31 March
2012, those who were dead, transferred out or lost to
follow-up, and those who did not present to a doctor or a
nurse at the clinic during the last quarter (January–
March 2012). Of those remaining in care, information is
provided on current drug management, the number and
proportion who had their blood pressure measured and
controlled in quarter 1, 2012, the number with one or
more late complications of disease and the numbers with
each complication. The commonest drugs used were
atenolol and enalapril (in about 75% of cases), followed by
hydrochlorothiazide and nifedipine (in about one-third of
Table 2 Quarterly cohort registration of patients with hyperten-
sion (HT) (January–March 2012)
Patient characteristics Number %
Patients with HT newly registered in the quarter 97
Gender
Male 46 47
Female 51 53
Age group in years: at time of registration
<20 0 0
20–39 14 14
40–59 56 58
60 and above 27 28
Category of disease: at time of registration
Hypertension only 47 48
Hypertension and diabetes 50 52
Diagnosis
New diagnosis of HT 52 54
Previous diagnosis of HT 45 46
Place of diagnosis
Inside UNRWA 60 62
Outside UNRWA 37 38
Transferred in 2 2
HT, hypertension; UNRWA, United Nations Relief and Works
Agency for Palestine Refugees in the Near East.
Table 3 Cumulative cohort registration of patients with hyper-
tension (HT) (patients ever registered up to 31 March 2012)
Patient characteristics Number %
All patients with HT ever registered,
including the new registrations between
January and March 2012.
4130
Gender
Male 1595 39
Female 2535 61
Age group in years: at time of registration
<20 5 <1
20–39 458 11
40–59 2443 59
60 and above 1224 30
Category of disease: at time of registration
Hypertension only 2148 52
Hypertension and diabetes 1982 48
Diagnosis
New diagnosis of HT 1442 35
Previous diagnosis of HT 2688 65
Previously diagnosed
Inside UNRWA 3333 81
Outside UNRWA 797 19
Transferred in 142 3
DM, diabetes mellitus; UNRWA, United Nations Relief and
Works Agency for Palestine Refugees in the Near East.
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measured in the most recent quarter, and of those 75% had
their hypertension controlled. One or more late complica-
tions were present in 15% of patients, with cardiovascular
disease and stroke accounting for most of the morbidity.
Finally, a quarterly cohort outcome analysis on patients
with HT newly registered 1 year previously (January–
March 2011) and assessed in quarter 1, 2012, is shown in
Table 5. This provides information about 12–15-month
outcomes, current management and late complications
within 1 year of registration, the number and proportion of
those who had blood pressure measured and controlled,
and the number and proportion that had annual screening
assessments performed (fasting blood glucose, total cho-
lesterol and serum creatinine) as recommended in the
UNRWA guidelines. While some assessments had been
well performed, others such as fasting blood glucose had
not. Similarly, there was no record of blood pressure
measurement in one quarter of patients who attended the
clinic between January and March 2012.
Discussion
This is the ﬁrst report from a primary healthcare clinic
setting to show how the ‘DOTS’ cohort monitoring system
can be adapted and used to monitor and report on persons
with HT in Jordan. This is potentially useful for the
UNRWA Hypertensive care services and can provide
information that is relevant and helpful for clinical disease
management programme performance, patient outcomes
and assessing long-term healthcare impact (Table 6). The
cohort monitoring system, particularly quarterly data on
new and cumulative cases, is also useful for public health
services planning and management, such as rational
forecasting for drugs and other consumables and all the
logistics necessary for providing quality care such as blood
pressure machines, treatment cards, etc.
The number of patients newly registered in the HT clinic
during a quarter provides informative data on ‘new
incident cases’, which can be further stratiﬁed by sex,
age, comorbid conditions such as diabetes mellitus and
Table 4 Cumulative cohort outcomes of
patients with hypertension (HT) (patients
ever registered up to 31 March 2012)
Patient characteristics and treatment outcomes Number %
All patients with HT ever registered, including the new
registrations between January and March 2012.
4130
Principal outcome as determined on 31 March 2012:
Remaining in care 3119 76
Dead 0 0
Transferred out 62 1.5
No attendance in quarter 1 (January–March) 2012 at the clinic 878 21
Lost to follow-up 71 1.5
Of patients remaining in care: current drug management 3119
Atenolol (beta-blocker) 2281 73
Propranolol (beta-blocker) 52 2
Amiloride (diuretic) 29 <1
Frusemide (diuretic) 391 1
Hydrochlorothiazide (diuretic) 1043 33
Frusemide injection (diuretic) 20 <1
Methyl Dopa 84 3
Nifedipine (calcium channel blocker) 889 29
Diltiazem (calcium channel blocker) 61 2
Enalapril (ACE inhibitor) 2366 76
Of patients remaining in care: blood pressure 3119
Number with blood pressure measured 2297 74
Number with blood pressure < 140⁄90 mmHg 1704 74
Of patients remaining in care: late complications 3119
Patients with one or more late complications 475 15
Patients who are blind 29 <1
Patients with end-stage renal disease 5 <1
Patients with myocardial infarction 237 8
Patients with congestive cardiac failure 118 4
Patients with stroke 144 5
Patients with above ankle amputation 1 <1
HT, hypertension: ACE inhibitor, angiotensin-converting enzyme inhibitor.
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data can be compared with those from the cumulative
registered cohort, allowing healthcare providers to assess
over time whether patient and disease characteristics and
the population’s access to care services are changing.
The cumulative number of patients alive and remaining
in care at a set moment in time (in this study by 31 March
2012) is an important piece of public health information
that indicates prevalent disease at the clinic (Harries et al.
2009b). This information helps the clinic staff to make
rational logistic plans and forecasts for consumables and
drugs. Adverse outcomes such as death and lost to
follow-up reﬂect to some extent clinic acceptability and
performance and also whether patients are accessing
services early or late. Of more relevance to immediate
management is the number of patients who failed to attend
the clinic in the quarter. E-Health could be used to identify
and ﬂag these patients, and, with the use of mobile
technology (Lester et al. 2010), attempts could be made to
encourage patients to attend the next quarter so that
continuity of care and uninterrupted drug intake are
maintained. Of patients who did attend the clinic in the last
quarter, about one quarter failed to have their blood
pressure measured. At the moment, it is uncertain whether
this reﬂects shortcomings in recording or non-adherence
to UNRWA guidelines (UNRWA Health Department
2009), but on both counts the two pieces of data indicate a
need for improved performance of either E-Health and⁄or
patient management.
While the cumulative outcome report provides a useful
cross-sectional analysis of the clinic programme at a set
point in time, it is limited by the fact that the time periods
of the E-health registered patients range from years (when
patients were ﬁrst entered into the E-Health system) to a
few days (the latest patients being entered just before the
censor date on 31 March 2012). This is the reason for the
12-month cohort outcome analysis that provides a much
better assessment of treatment outcomes, clinical manage-
ment performance and quality of control for a smaller
group of patients registered over a three-month period, in
this case 1 January to 31 March 2011, with outcomes
assessed 12 months in the future. This is not strictly a
12-month outcome analysis as some patients are followed
for up to 15 months, but in the context of routine
monitoring, this is good enough to inform about pro-
gramme performance. This cohort analysis is a useful way
of assessing whether interventions as speciﬁed in UNRWA
guidelines are being performed and whether blood pressure
is being controlled. The number with late complications at
1 year after registration also provides a baseline assessment
from which to compare serious morbidity during long-term
follow-up in 2, 5 or 10 years time.
Table 5 Twelve to 15-month cohort outcome analysis of patients
with hypertension*
Patient characteristics Number %
Patients with HT newly registered
in quarter 1 (January–March) 2011
226
Principal outcome as determined on 31 March 2012
Remaining in care 140 62
Dead 0 0
Transferred out 2 <1
No quarterly attendance at the clinic
in quarter 1, 2012
84 38
Lost to follow-up 0 0
Of those remaining in care:
current management
140
Atenolol (beta-blocker) 93 66
Propranolol (beta-blocker) 2 1
Amiloride (diuretic) 0 0
Frusemide (diuretic) 8 6
Hydrochlorothiazide (diuretic) 31 22
Frusemide injection (diuretic) 1 <1
Methyl Dopa 3 2
Nifedipine (calcium channel blocker) 24 17
Diltiazem (calcium channel blocker) 0 0
Enalapril (ACE inhibitor) 101 72
Of those remaining in care: blood pressure
in current quarter
140
Patients with blood pressure measured 104 74
Patients with blood pressure
< 140⁄90 mmHg
79 76
Of those remaining in care:
annual assessment
140
Patients with HT only 79 56
In patients with HT only,
FBG measured
23
Of those, FBG £ 180 mg⁄dl 1 50
In those with HT and HT-DM,
total cholesterol measured
140 100
Of those, total cholesterol < 200 mg⁄dl 89 64
In those with HT and HT-DM,
serum creatinine measured
139 99
Of those, serum creatinine < 1.2 mg⁄dl 130 94
Of those remaining in care:
late complications
140
Patients with one or more
late complications
11 8
Patients who are blind 0 0
Patients with end-stage
renal disease
00
Patients with myocardial
infarction
86
Patients with congestive cardiac failure 1 <1
Patients with stroke 2 1
Patients with above ankle amputation 0 0
HT, hypertension; DM, diabetes mellitus: FBG, fasting blood
glucose; ACE inhibitor, angiotensin-converting enzyme inhibitor.
*Patients newly registered with HT between January and March
2011 and assessed 12 months later in quarter 1, 2012.
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data on a quarterly basis, and this will enable the
programme to look at whether performance and disease
control in later cohorts are improving. E-Health is essential
for enabling this type of cohort analysis to work as using
paper-based registers and cards to do manual calculation of
cohorts and outcomes is too time-consuming and takes
health staff away from patient care (Douglas et al. 2010).
The experience also shows the advantage of embracing
new E-Health technology in routine primary healthcare
services. Time will tell whether the quarterly cohort
reporting can be continued under the routine system and
whether hitherto unrecognised difﬁculties become apparent
over time. However, it is clear that where such electronic
medical record systems are not in place, this type of cohort
reporting may be too difﬁcult and time-consuming to do
using a paper-based record and this is a downside of the
current approach.
In conclusion, the use of E-Health and cohort reporting
is seen as a valuable monitoring tool for managing HT in
Palestine refugees. UNRWA has decided to expand cohort
analysis to the other PHC clinics in Jordan that already
have E-Health as well as expand E-Health to all PHC
clinics in the country and to other ﬁelds where UNRWA
operates, namely West Bank, Gaza Strip, Lebanon and
Syria. Doing so should ultimately lead to improved patient
outcomes and better health status.
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